AbbVie Inc. Stock
€187.20
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade
Key Points
- Interested in AbbVie Inc.? Here are five stocks we like better.
- Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
AbbVie's (NYSE: ABBV) share price has been under pressure due to rising costs and concerns that its post-Humira days won’t be as robust. However, the stock price decline put the market in a
3 Companies Aggressively Raising Dividends While Others Play Defense
Dividend growth stocks may be worth a closer look heading toward the midpoint of 2026, given extreme geopolitical turbulence and concerns about inflation or a recession that are sending skittish
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal
When the price of a high-quality stock such as AbbVie (NYSE: ABBV) declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to
AbbVie Call Options Spike 2,599%: Tracking the Big Bet
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
Despite its shares being in the red year to date, AbbVie's (NYSE: ABBV) financial results have been strong. The company's first-quarter update, released on April 29, came in ahead of expectations on
3 Dividend Stocks to Buy and Hold Forever
The healthcare sector has faced challenges in recent years due to regulatory pressures and a somewhat uncertain outlook. However, thanks in part to its defensive nature and the fact that excellent
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both giants face patent cliffs but pursue very different
What's the Better Dividend Stock Today: AbbVie or Pfizer?
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two top healthcare stocks, and they're investments that can generate a ton of dividend income for your portfolio.
AbbVie, which yields 3.2%, has been a
The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
When investors are in a risk-on mood, they often gravitate to growth-oriented technology stocks. When investors are in a risk-off mood, however, they often rotate out of tech and into other areas
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
Let's face it: We live in uncertain times. There's no clear end in sight to the war with Iran. Fuel prices seem likely to remain elevated for a while, likely pushing the costs of a wide range of
2 Stocks That Are Much Cheaper Than They Look
Simply looking at earnings numbers and multiples can be misleading if you're looking at stocks to buy. That's because a company can have an unusually strong or weak quarter that impacts its
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow
If you're in the market for a healthcare stock for your long-term portfolio, give some consideration to AbbVie (NYSE: ABBV). It's a drug company that was spun off from Abbott Laboratories in 2013
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
AbbVie's (NYSE: ABBV) financial results have been pretty strong lately. In its first-quarter update released on April 29, it generated $15 billion in revenue -- above its own guidance of $14.7
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?
There are plenty of dividend stocks on equity markets. Few are more secure than Dividend Kings, a group of corporations that have raised their payouts annually for at least 50 years straight. This
AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook
AbbVie (NYSE: ABBV) has not performed well this year, but the company's recent first-quarter update, released on April 29, helped breathe new life into the stock, which jumped by more than 3%
Should You Buy AbbVie Stock Hand Over Fist Before April 29?
AbbVie (NYSE: ABBV), a pharmaceutical giant, is set to release its first-quarter earnings report on April 29. The stock has not performed well so far this year, with shares down 13% as of writing.
Why AbbVie Is a No-Brainer Stock to Buy on the Dip
AbbVie's (NYSE: ABBV) stock closed at a record high of $238.71 on Oct. 1, 2025. However, its stock has pulled back by about 13% since then. Let's see why that pullback represents a golden buying
Could AbbVie Crash Lilly's Weight‑Loss Party?
AbbVie's (NYSE: ABBV) most important therapeutic area has historically been immunology, where it has marketed billion-dollar drugs like Humira, which was once the world's best-selling medicine. The
S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend.
Don't look now, but the S&P 500 index is becoming something of a desert for income investors. As reported recently by Yahoo! Finance, the average dividend yield of all 500 titles has shriveled to
Could Buying This Dividend Pharma Stock Today Set You Up for Life?
If you are a retiree looking to supplement your Social Security checks with income you derive from dividend stocks, you'll want to get to know Johnson & Johnson (NYSE: JNJ). It has a dividend record
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade
AbbVie (NYSE: ABBV), spun off from Abbott Laboratories in 2013, has raised its quarterly dividend each year since becoming an independent, publicly traded company. This comes even as the North
Should You Buy AbbVie Stock Before April 29?
AbbVie (NYSE: ABBV) is a leading drugmaker that investors have come to rely on for steady and consistent results over the years. Along the way, it has also paid and increased its dividend on a
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory
Many tech stocks have moved lower, along with the tech-heavy Nasdaq Composite, in recent months. This is partly because there are growing fears of a recession. While some beaten-down companies could